Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/11/2011

arned in 2009 and 2010 resulted from the recognition of a portion of the $35 million, upfront, non-refundable license fee under the Bayer agreement and the related reimbursement by Bayer of third-party development costs.  In addition, in 2010, the Company recognized $15.0 million in revenue for the achievement of the first milestone, as well as approximately $0.4 million in sponsored research revenue, under the license agreement with Bayer.  

For the three and twelve months ended December 31, 2010, total operating expenses increased to $17.8 million and $68.6 million, respectively, from $14.4 million and $52.9 million for the same periods in 2009.  Total operating expenses for the three and twelve months ended December 31, 2010 included non-cash stock-based compensation charges of $1.8 million and $10.8 million, or $0.08 per share and $0.49 per share, respectively, as compared to charges of $1.4 million and $5.8 million, or $0.08 per share and $0.32 per share, respectively, for the same periods in 2009. These increased charges were primarily in connection with the departure of certain employees during the third quarter of 2010.  The increase in total operating expenses between the 2009 and 2010 periods was primarily a result of an increase in research and development expense due mainly to the continued development and progression of our clinical and preclinical programs, as well as the above-described increase in non-cash, stock-based compensation expense.

Net loss for the three and twelve months ended December 31, 2010 was $0.6 million and $41.6 million, or $0.03 per share and $1.91 per share, respectively, compared to a net loss for the same periods in 2009 of $6.3 million and $30.9 million, or $0.34 per share and $1.70 per share, respectively.   The decrease in net loss between the three-month periods and the increase in net loss between the twelve-month periods were due primarily to the revenue and operating expen
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Ardea Biosciences to Present at Two Upcoming Investor Conferences
10. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
11. Ardea Biosciences Prices Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Chelating ... About Chelating Agent A chelating ... covalent bonds with metal ions, thereby forming a ... some metal-ions have on chemical processes, formulations, and ...
(Date:8/27/2014)... Aug. 27, 2014  A novel biomarker for ... physicians better identify early-stage disease, when treatment can ... to a new study in The Journal of ... DGX ) and other institutions found ... outperformed conventional antibody-serum testing, including rheumatoid factor (RF) ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... Research and Markets  has announced the ... Spectrometer Industry Report 2014" report to their offering. ... Spectrometer Industry Report 2014 is a professional and in-depth ... ratio mass spectrometer industry. The report provides ... applications and industry chain structure. The isotope ratio mass ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... TRIANGLE PARK, N.C., Nov. 17, 2010 Chimerix, Inc., ... an update to the World Health Organization (WHO) on ... at the 12th Meeting of the WHO Advisory Committee ... of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 ...
... SEATTLE, Nov. 17, 2010 Cell Therapeutics, Inc. ("CTI") ... Medicines Agency ("EMA") approved CTI,s Pixuvri (pixantrone dimaleate) Pediatric ... and solid tumors in children between the ages of ... (the "PDCO") of the EMA adopted an opinion agreeing ...
... Researchers have demonstrated a new imaging tool for ... hastening their use in creating a new class ... consume less power than today,s. The semiconducting ... replacing conventional silicon components and circuits. However, one ...
Cached Biology Technology:Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 2Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research 3European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 2European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri 3Imaging tool may aid nanoelectronics by screening tiny tubes 2Imaging tool may aid nanoelectronics by screening tiny tubes 3
(Date:8/27/2014)... invasive grass species frequently found in forests has created ... on American toads, a new University of Georgia study ... to the U.S. in the early 1900s, is one ... to more than a dozen states in the past ... and in forests, it can survive in widely diverse ...
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... that exists as five strains, none of which have ... the Sudan ebolavirus (SUDV). Although not the strain currently ... as recently as 2012. In a new study appearing ... now report a possible therapy that could someday help ... Sidhu, Jonathan Lai and colleagues explain that about 50-90 ...
Breaking Biology News(10 mins):More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... of British Columbia and the Child & Family Research Institute ... a type of T cell in type 1 diabetes that ... Also known as juvenile diabetes, type 1 diabetes is an ... with type 1 diabetes, the body attacks itself by destroying ...
... to the National Heart, Lung and Blood Institute, the average ... and 30 times a night. This lack of oxygen leads ... disease, an abnormal heart rhythm, or even a fatal cardiac ... exploring the changes in distinct brain regions that contribute to ...
... The National Institute of Environmental Health Sciences has ... Shaw for a five-year study of how the ... selection. The project reflects a changing ... advances in molecular toxicology, computational sciences and information ...
Cached Biology News:Researchers study sleep apnea and lack of oxygen 2Researcher awarded $2.27 million to study environmental effects on gene copy number 2Researcher awarded $2.27 million to study environmental effects on gene copy number 3Researcher awarded $2.27 million to study environmental effects on gene copy number 4
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: